highly significantp = 0.025
On the other hand, the authors also indicated that the number of three or more comorbidities per se was highly significant for a no-tocilizumab treatment decision (comorbidity count p = 0.025).
1
0.0250
0.0250
On the other hand, the authors also indicated that the number of three or more comorbidities per se was highly significant for a no-tocilizumab treatment decision (comorbidity count p = 0.025).